Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010

Medical Journal of Australia

Volumn 196, Issue 10, 2012, Pages 642-645

  Handelsman, David J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

REANDRON; TESTOSTERONE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG; ANDROGEN;

ARTICLE; AUSTRALIA; COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG INDICATION; GEL; HEALTH CARE COST; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; TRANSDERMAL PATCH; TREND STUDY; CLINICAL PRACTICE; ECONOMICS; HUMAN; MALE;

ANDROGENS; AUSTRALIA; HEALTH EXPENDITURES; HUMANS; MALE; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; TESTOSTERONE;

EID: 84865077426     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.11277     Document Type: Article

References (24)

1. Butenandt A, Hanisch G. [Uber die Umwandlung des Dehydroandrosterons in Androstenol-(17)-one-(3) (Testosterone); Umweg zur darstellung des testosterons aus Cholsterin (vorlauf mitteilung)] [German]. Zeischrift Physiologische Chemie 1935; 237: 89-97.
2. David K, Dingmanse E, Freud J, et al. [Uber krystallinisches mannliches Hormon aus Hoden (Testosteron), wirksamer als aus Harn oder aus Cholestrin bereites Androsteron] [German]. Zeischrift Physiologische Chemie 1935; 233: 281-282.
3. Ruzicka L, Wettstein A. [Uber die krystallische Herstellung des Testikelhormons, Testosteron (androsten-3-on-17-ol)] [German]. Helv Chim Acta 1935; 18: 1264-1275.
4. Hamilton JB. Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 1937; 21: 649-654.
5. Handelsman DJ. Androgen physiology, pharmacology and abuse. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 6th ed. Philadelphia: Elsevier Saunders, 2010: 2469-2498.
6. Handelsman DJ. Trends and regional differences in testosterone prescribing in Australia, 1991-2001 Med J Aust 2004; 181: 419-422.
7. Fennell C, Sartorius G, Ly LP, et al. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 2010; 73: 102-109.
8. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673-2681.
9. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91: 69-74.
10. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500-4510.
11. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000; 85: 964-969.
12. Handelsman DJ, Liu PY. Klinefelter's syndrome-a microcosm of male reproductive health. J Clin Endocrinol Metab 2006; 91: 1220-1222.
13. Herlihy AS, Halliday JL, Cock ML, McLachlan RI. The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison. Med J Aust 2011; 194: 24-28.
14. Liverman CT, Blazer DG, editors. Testosterone and aging: clinical research directions. Washington, DC: The National Academies Press, 2004. http:// www.nap.edu/catalog.php?record_id=10852 (accessed Feb 2012).
15. Conway AJ, Handelsman DJ, Lording DW, et al; Endocrine Society of Australia. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000; 172: 220-224.
16. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
17. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of lateonset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125-127.
18. Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
19. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of lateonset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30: 1-9.
20. Wu FC, Tajar A, Beynon JM, et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135.
21. Handelsman DJ. An old emperor finds new clothing: rejuvenation in our time. Asian J Androl 2011; 13: 125-129.
22. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
23. Shabsigh R. Testosterone therapy in erectile dysfunction. Aging Male 2004; 7: 312-318.
24. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764-1767.